{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+sequence+C&page=2", "query": { "intervention": "Treatment sequence C", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+sequence+C&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-16T11:31:11.407Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07723833", "title": "A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "Elecoglipron Reference Formulation Dose A", "type": "DRUG" }, { "name": "Elecoglipron Test formulation 1 Dose A", "type": "DRUG" }, { "name": "Elecoglipron Reference Formulation Dose B", "type": "DRUG" }, { "name": "Elecoglipron Test formulation 1 Dose B", "type": "DRUG" }, { "name": "Elecoglipron Test formulation 2 Dose A", "type": "DRUG" }, { "name": "Elecoglipron Test formulation 2 Dose B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 152, "start_date": "2026-07-27", "completion_date": "2026-11-18", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-16T11:31:11.407Z", "location_count": 2, "location_summary": "Glendale, California • Brooklyn, Maryland", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Brooklyn", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07723833" }, { "nct_id": "NCT02082808", "title": "Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "DTG", "type": "DRUG" }, { "name": "DCV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 12, "start_date": "2014-03", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2014-06-09", "last_synced_at": "2026-09-16T11:31:11.407Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02082808" }, { "nct_id": "NCT02851212", "title": "A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]", "type": "DRUG" }, { "name": "Canagliflozin", "type": "DRUG" }, { "name": "Metformin Extended Release (XR)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 44, "start_date": "2016-08", "completion_date": "2016-10", "has_results": false, "last_update_posted_date": "2016-12-02", "last_synced_at": "2026-09-16T11:31:11.407Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02851212" }, { "nct_id": "NCT02723630", "title": "Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Lenvatinib 10 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 60, "start_date": "2013-07", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2019-03-14", "last_synced_at": "2026-09-16T11:31:11.407Z", "location_count": 1, "location_summary": "Las Vegas, Nevada", "locations": [ { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT02723630" }, { "nct_id": "NCT04647383", "title": "A Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Participants With Moderate to Severe Obstructive Sleep Apnea, and in Adult and Elderly Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sleep Apnea, Obstructive", "Pulmonary Disease, Chronic Obstructive", "Respiration Disorders" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Lemborexant 10 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "45 Years to 90 Years" }, "enrollment_count": 63, "start_date": "2021-01-06", "completion_date": "2022-02-10", "has_results": true, "last_update_posted_date": "2023-10-10", "last_synced_at": "2026-09-16T11:31:11.407Z", "location_count": 11, "location_summary": "Glendale, Arizona • San Diego, California • Brandon, Florida + 7 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Brandon", "state": "Florida" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04647383" }, { "nct_id": "NCT06293742", "title": "ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "ECC5004", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eccogene", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 48, "start_date": "2024-02-08", "completion_date": "2024-04-15", "has_results": false, "last_update_posted_date": "2024-07-22", "last_synced_at": "2026-09-16T11:31:11.407Z", "location_count": 1, "location_summary": "Anaheim, California", "locations": [ { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06293742" }, { "nct_id": "NCT03647202", "title": "Food Effects on Milademetan Pharmacokinetics in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Food Effects on Pharmacokinetics" ], "interventions": [ { "name": "Milademetan Treatment A", "type": "DRUG" }, { "name": "Milademetan Treatment B", "type": "DRUG" }, { "name": "Milademetan Treatment C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 18, "start_date": "2018-08-16", "completion_date": "2018-09-13", "has_results": false, "last_update_posted_date": "2019-02-12", "last_synced_at": "2026-09-16T11:31:11.407Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03647202" }, { "nct_id": "NCT02608320", "title": "A Study to Evaluate the Adherence of 2 Strengths of Newly Manufactured Samples and Aged Samples of a New Formulation (JNJ-35685-AAA-G016 and JNJ-35685-AAA-G021) of Fentanyl Transdermal System Compared With Duragesic Fentanyl Transdermal Patch in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Duragesic (Fentanyl Transdermal System [TDS] Small Patches)", "type": "DRUG" }, { "name": "New JNJ-35685-AAA-G016 (Fentanyl TDS -Small Patches)", "type": "DRUG" }, { "name": "Aged JNJ-35685-AAA-G016 (Fentanyl TDS Small Patches)", "type": "DRUG" }, { "name": "Duragesic (Fentanyl TDS Large Patches)", "type": "DRUG" }, { "name": "New JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)", "type": "DRUG" }, { "name": "Aged JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 52, "start_date": "2015-11-17", "completion_date": "2016-04-13", "has_results": false, "last_update_posted_date": "2025-02-03", "last_synced_at": "2026-09-16T11:31:11.407Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02608320" }, { "nct_id": "NCT03438461", "title": "A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Seltorexant 40 mg", "type": "DRUG" }, { "name": "Seltorexant 20 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 49, "start_date": "2018-02-09", "completion_date": "2018-05-30", "has_results": false, "last_update_posted_date": "2025-04-27", "last_synced_at": "2026-09-16T11:31:11.407Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03438461" }, { "nct_id": "NCT02282527", "title": "A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Alpha₁-Antitrypsin Deficiency" ], "interventions": [ { "name": "Liquid Alpha₁-PI", "type": "BIOLOGICAL" }, { "name": "Prolastin-C", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Grifols Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 32, "start_date": "2014-10", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2017-03-13", "last_synced_at": "2026-09-16T11:31:11.407Z", "location_count": 6, "location_summary": "Denver, Colorado • Gainesville, Florida • Miami, Florida + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Wilmington", "state": "North Carolina" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02282527" } ] }